Angiogenesis
Angiogenesis inhibitors are compounds that interfere with the formation of new blood vessels, a process critical in cancer growth and metastasis. By inhibiting angiogenesis, these compounds can restrict the blood supply to tumors, slowing or halting their growth. Angiogenesis inhibitors are essential in cancer research and therapeutic development, providing insights into the mechanisms of tumor progression and offering potential treatments for cancer and other angiogenesis-related diseases. At CymitQuimica, we offer a wide range of high-quality angiogenesis inhibitors to support your research in oncology and vascular biology.
Subcategories of "Angiogenesis"
- BTK(166 products)
- Bcr-Abl(118 products)
- EGFR(582 products)
- FAK(72 products)
- FLT(86 products)
- Fibroblast Growth Factor Receptor (FGFR)(180 products)
- JAK(243 products)
- PDGFR(129 products)
- RAAS(89 products)
- Src(82 products)
- Syk(37 products)
- Thrombin(57 products)
- VDA(2 products)
- VEGFR(242 products)
Show 6 more subcategories
Found 2382 products of "Angiogenesis"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
PI3K/VEGFR2-IN-1
CAS:PI3K/VEGFR2-IN-1 is a potent dual inhibitor targeting both PI3K and VEGFR2 with IC50 values of 2.21 μM for PI3K and 68 μM for VEGFR2, respectively.Formula:C17H14ClN3OSPurity:98%Color and Shape:SolidMolecular weight:343.83TYRA-300
CAS:TYRA-300 is an oral and selective FGFR3 inhibito, in the Ba/F3 cell line for the treatment of metastatic uroepithelial carcinomas (mUCs) and chondrodysplasia.Formula:C25H24Cl2N6O3SPurity:99.66%Color and Shape:SolidMolecular weight:559.47Ref: TM-T88841
1mg382.00€5mg696.00€10mg947.00€25mg1,554.00€50mg2,034.00€100mg2,749.00€1mL*10mM (DMSO)856.00€EGFR-IN-32
CAS:EGFR-IN-32, a potent EGFR blocker, shows promise for EGFR-mutated illnesses. (Patent WO2021185297A1, compound 2)Formula:C31H34N6O3Color and Shape:SolidMolecular weight:538.64Irpagratinib
CAS:Irpagratinib (ABSK011) is an FGFR4 antagonist with anticancer activity, inhibiting FGFR4 autophosphorylation and blocking downstream signaling pathways.Formula:C28H32F2N6O5Purity:99.08% - 99.38%Color and Shape:SolidMolecular weight:570.59Tyrphostin AG1433
CAS:Tyrphostin AG1433 (AG1433) is an inhibitor of tyrosine kinases and also a dual inhibitor of PDGFRβ(IC50s = 5.0 μM) and VEGFR-2 (Flk-1/KDR)(IC50s = 9.3 μM).Formula:C16H14N2O2Purity:98.47%Color and Shape:SolidMolecular weight:266.29Infigratinib-Boc
CAS:Infigratinib-Boc, a derivative of the ATP-competitive pan-FGFR inhibitor Infigratinib, incorporates a Boc (t-Butyloxy carbonyl) group [1].Formula:C29H35Cl2N7O5Color and Shape:SolidMolecular weight:632.54SG3-179
CAS:SG3-179 is a BET inhibitor.Formula:C28H35ClFN7O3SColor and Shape:SolidMolecular weight:604.14ALK/EGFR-IN-3
CAS:ALK/EGFR-IN-3 is a dual ALK and EGFR inhibitor that demonstrates potent anti-proliferative effects on various cancer cell lines, including H1975, PC9, and Baf3-Formula:C27H34ClN7O3SColor and Shape:SolidMolecular weight:572.12AT-9283 L-lactate
CAS:AT-9283 L-lactate is an inhibitor of aurora kinase.Formula:C22H29N7O5Purity:98%Color and Shape:SolidMolecular weight:471.52EGFR-IN-36
CAS:EGFR-IN-36 inhibits EGFR, HER2, & mutants with IC50s: 19.09 nM (EGFR WT), 120.01 nM (HER2 WT), 2.35 nM (HER2 mutant).Formula:C26H25ClN6O2Color and Shape:SolidMolecular weight:488.97Nezulcitinib
CAS:Nezulcitinib (TD-0903) is an inhaled pan-JAK inhibitor targeting COVID-19-related acute lung injury.Formula:C30H37N7O2Color and Shape:SolidMolecular weight:527.66FGFR3-IN-7
CAS:FGFR3-IN-7 is a potent, selective inhibitor of FGFR 3, demonstrating an IC50 value of less than 350 nM , and is utilized in cancer research [1].Formula:C25H24FN9OPurity:98%Color and Shape:SolidMolecular weight:485.52FGFR3-IN-6
CAS:FGFR3-IN-6 is a potent, selective inhibitor of FGFR 3, exhibiting an IC50 value of less than 350 nM , and is utilized in cancer research [1].Formula:C25H23FN8O2Purity:98%Color and Shape:SolidMolecular weight:486.5QL-1200186
CAS:QL-1200186 is an orally active, selective TYK2 inhibitor that, upon dose-dependent oral administration, suppresses interferon-γ (IFNγ) production followingFormula:C26H27N7O3Purity:98%Color and Shape:SolidMolecular weight:485.54TIE-2/VEGFR-2 kinase-IN-4
CAS:TIE-2/VEGFR-2 kinase-IN-4, a benzimidazole derivative, serves as a potent inhibitor of the tyrosine kinase receptors TIE-2 and VEGFR-2, exhibiting inhibitoryFormula:C26H17F4N5O4Color and Shape:SolidMolecular weight:539.44JAK2-IN-4
CAS:JAK2-IN-4 is a selective JAK2/JAK3 inhibitor, with IC50 values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively.Formula:C23H27N5O4SPurity:98%Color and Shape:SolidMolecular weight:469.56CCT365623 hydrochloride
CAS:CCT365623 hydrochloride is an orally active inhibitor of lysyl oxidase (LOX) (IC50: 0.89 μM). It suppresses EGFR (pY1068) and AKT phosphorylation driven by EGF.Formula:C18H18ClNO4S3Purity:98%Color and Shape:SolidMolecular weight:443.99CT-721
CAS:CT-721: potent, time-bound Bcr-Abl inhibitor, IC50 21.3 nM, effective against CML.Formula:C30H29ClN6OPurity:98%Color and Shape:SolidMolecular weight:525.04(Z)-RG-13022
CAS:(Z)-RG-13022 is a tyrosine kinase (TK) inhibitor that preferentially inhibits the TK activity of the EGF receptor, restricting the EGF-stimulated growth of cultured cells. It demonstrates an IC50 of 11 μM for DNA synthesis in HN5 cells, showcasing thrice the potency of its isomer, (E)-RG-13022 (IC50 = 38 μM). This compound is applied in breast cancer cell research [1] [2].Formula:C16H14N2O2Color and Shape:SolidMolecular weight:266.29FGFR-IN-11
CAS:FGFR-IN-11 (compound I-5) is an orally active, covalent inhibitor of FGFR, exhibiting IC50 values of 9.9 nM (FGFR1), 3.1 nM (FGFR2), 16 nM (FGFR3), and 1.8 nM (Formula:C28H29ClN4O4Purity:98%Color and Shape:SolidMolecular weight:521.01NMS-P953
CAS:NMS-P953: JAK2 inhibitor, reduces tumor growth in SET-2 model, confirmed in vivo action, good pharmacokinetics and safety.Formula:C16H11ClF3N5OColor and Shape:SolidMolecular weight:381.74Pirtobrutinib
CAS:Pirtobrutinib: a selective, non-covalent BTK inhibitor effective against BTK C481 mutations, causing tumor regression in lymphoma models.Formula:C22H21F4N5O3Purity:99.76% - 99.94%Color and Shape:SolidMolecular weight:479.43Ref: TM-T36287
1mg34.00€5mg74.00€10mg119.00€25mg268.00€50mg411.00€100mg605.00€500mg1,288.00€1mL*10mM (DMSO)79.00€Tyk2-IN-9
CAS:Tyk2-IN-9: selective Tyk-2 inhibitor, IC50 of 0.076 nM (TYK2-JH2), 1.8 nM (JAK1-JH2), for inflammation/autoimmune research.Formula:C20H17N9Purity:98%Color and Shape:SolidMolecular weight:383.41EGFR/CSC-IN-1
CAS:EGFR/CSC-IN-1 is a dual inhibitor targeting both the epidermal growth factor receptor (EGFR [IC50 10.52 nM]) and cancer stem cells (CSC), with potentialFormula:C54H54Cl2FN7O7S2Purity:98%Color and Shape:SolidMolecular weight:1067.08TIE-2/VEGFR-2 kinase-IN-5
CAS:TIE-2/VEGFR-2 kinase-IN-5 is a TIE-2 and VEGFR-2 tyrosine kinase receptor inhibitor commonly used in biomedical research related to angiogenesis.Formula:C21H13F6N5O2Purity:99.79%Color and Shape:SolidMolecular weight:481.35Sulfatinib
CAS:Sulfatinib (KDR-IN-1) (HMPL-012) is a potent and highly selective tyrosine kinase inhibitor against VEGFR1/2/3, FGFR1 and CSF1R with IC 50 s ranging from 1 toFormula:C24H28N6O3SPurity:99.21% - >99.99%Color and Shape:SolidMolecular weight:480.58VEGFR2-IN-3
CAS:VEGFR2-IN-3 (compound 385) is a potent inhibitor of VEGFR2 [1].Formula:C26H28ClN5O4Purity:98%Color and Shape:SolidMolecular weight:509.98Lepzacitinib
CAS:Lepzacitinib is a selective, inflammatory, small molecule JAK1/3(Janus kinase) inhibitor primarily used for the treatment of atopic dermatitis.Formula:C18H21N5O3Purity:99.85%Color and Shape:SolidMolecular weight:355.39Ref: TM-T78207
1mg50.00€5mg104.00€10mg167.00€25mg340.00€50mg505.00€100mg712.00€200mg1,009.00€1mL*10mM (DMSO)114.00€JAK-IN-1
CAS:JAK-IN-1 shows improved selectivity for JAK3 over JAK1. JAK-IN-1 is a JAK1/2/3 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively.Formula:C20H24N6O2Purity:98%Color and Shape:SolidMolecular weight:380.44EGFR/HER2-IN-11
CAS:EGFR/HER2-IN-11 (compound 20), an orally active dual inhibitor targeting human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), demonstrates IC50 values of 7.7 nM and 22 nM, respectively. This compound shows strong antitumor efficacy, specifically inhibiting the proliferation of BT-474 cancer cells with a GI50 of 601 nM [1].Formula:C23H21ClF3N5O2Color and Shape:SolidMolecular weight:491.89ALK-IN-6
CAS:ALK-IN-6 is an orally bioavailable inhibitor of anaplastic lymphoma kinase (ALK, IC50s: 71 nM, 18.72 nM, and 36.81 nM for ALK wild, ALK F1196M and ALK F1174L).Formula:C26H29ClD3N5O3SPurity:98%Color and Shape:SolidMolecular weight:533.1MTP
CAS:MTP, a PKM2 inhibitor, promotes apoptosis in cancer cells via caspase-3 activation while also inducing autophagy and enhancing ROS generation.Formula:C29H23F3N4O2Purity:98%Color and Shape:SolidMolecular weight:516.51Tubulin/JAK2-IN-1
CAS:Tubulin/JAK2-IN-1 (compound 7g) serves as a potent dual inhibitor targeting both Janus kinase 2 (JAK2) and microtubules, demonstrating significantFormula:C22H20N6O3Color and Shape:SolidMolecular weight:416.43TAK-659
CAS:TAK-659 is a spleen tyrosine kinase (SYK) inhibitor.Formula:C17H21FN6OPurity:98%Color and Shape:SolidMolecular weight:344.39FGFR4-IN-8
CAS:FGFR4-IN-8 is a selective, ATP-competitive FGFR4 inhibitor with IC50s as low as 0.25 nM, halting growth of Hep3B cells at 29 nM and showing in vivo efficacy.Formula:C32H34Cl2FN7O3Purity:98%Color and Shape:SolidMolecular weight:654.56Brolucizumab
CAS:Brolucizumab (anti-VEGF-A scFv) potently blocks VEGF-A to reduce neovascularization in wet AMD, with picomolar binding affinity.Purity:95%Color and Shape:LiquidMolecular weight:~150 kDaN-desmethyl Regorafenib N-oxide
CAS:N-Desmethyl Regorafenib N-oxide, an active metabolite of the multi-kinase inhibitor regorafenib, originates through the action of the cytochrome P450 (CYP) isoform CYP3A4. This compound demonstrates efficacy in vitro by inhibiting key enzymes such as VEGFR2, Tie2, c-Kit, and B-RAF, and it exhibits tumor growth inhibition in HT-29 and MDA-MB-231 mouse xenograft models at a dosage of 1 mg/kg.Formula:C20H13ClF4N4O4Color and Shape:SolidMolecular weight:484.79GW-6604
CAS:GW-6604 is an ALK5 inhibitor and shows clear antifibrotic effects resulting in liver function improvement.Formula:C19H14N4Purity:99.6%Color and Shape:SolidMolecular weight:298.34BMS-599626 Hydrochloride
CAS:BMS-599626 HCl (AC480 HCl) is an oral inhibitor of HER1, HER2, HER4 kinases, potentially blocking tumor growth. IC50: 22/32/190 nM.Formula:C27H28ClFN8O3Purity:99.98%Color and Shape:SolidMolecular weight:567.01Rocbrutinib
CAS:Rocbrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that exhibits antineoplastic properties [1].Formula:C42H51N9O5Color and Shape:SolidMolecular weight:761.91BEBT-109
CAS:BEBT-109 is a selective epidermal growth factor receptor (EGFR) inhibitor that shows anti-tumor activity in EGFR-mutant non-small cell lung cancer.Formula:C27H32N8O3Purity:97.26%Color and Shape:SolidMolecular weight:516.6Resigratinib
CAS:Resigratinib (KIN-3248) is an oral, irreversible pan-FGFR family protein inhibitor, covalently binds to and inhibits all four FGFR isoforms(FGFR1/2/3/4).Formula:C26H27F2N7O3Purity:98.58%Color and Shape:SolidMolecular weight:523.53TCJL37
CAS:TCJL37: potent, selective TYK2 inhibitor (K i 1.6 nM), oral, for IBD research.Formula:C17H11ClF2N4O2Color and Shape:SolidMolecular weight:376.74EGFR-IN-61
CAS:EGFR-IN-61 inhibits EGFR kinase (IC50: 42 nM L858R/T790M, 137 nM L858R/T790M/C797S, 743 nM WT) and slows A549 & H1975 cell growth (IC50: 2.14 & 1.82 μM).Formula:C33H37ClN8O3Purity:98%Color and Shape:SolidMolecular weight:629.15YS-363
CAS:YS-363 is a potent, selective, and orally active inhibitor of the epidermal growth factor receptor (EGFR), exhibiting half-maximal inhibitory concentrations (Formula:C30H30N4O3Purity:98%Color and Shape:SolidMolecular weight:494.58JAK-IN-24
CAS:JAK-IN-24: JAK inhibitor, IC50: 0.534 nM (4 μM ATP), 24 nM (1mM ATP), STAT5 phosphorylation IC50: 86.171 nM.Formula:C20H25N5O2Color and Shape:SolidMolecular weight:367.44SNIPER(TACC3)-11
CAS:SNIPER(TACC3)-11 is a powerful FGFR3-TACC3 protein degrader, reducing its amount and hindering FGFR3-TACC3+ cancer cell growth.Formula:C51H66N10O7S2Color and Shape:SolidMolecular weight:995.26SD 1008
CAS:SD 1008 is a JAK2/STAT3 signaling pathway inhibitor. SD 1008 inhibits activation of STAT3, JAK2, and Src.Formula:C18H19NO5Purity:98%Color and Shape:SolidMolecular weight:329.35DosatiLink-2
CAS:DosatiLink-2 is an inhibitor of the Abelson murine leukemia (ABL) enzyme [1].Formula:C65H85Cl2F2N13O15SColor and Shape:SolidMolecular weight:1429.42BTK-IN-11
CAS:BTK-IN-11: potent BTK inhibitor; may research autoimmune, inflammatory diseases, cancer. (Patent WO2022063101A1, Z2)Formula:C26H22ClN5O3Color and Shape:SolidMolecular weight:487.94FGFR-IN-8
CAS:FGFR-IN-8, potent oral FGFR inhibitor for wild-type/mutant types, induces apoptosis with anti-cancer properties.Formula:C27H31Cl2N9O2Color and Shape:SolidMolecular weight:584.5Brepocitinib
CAS:Brepocitinib (PF-06700841) is a potent dual JAK1/TYK2 inhibitor (IC50s: 17 nM/23 nM). Brepocitinib also inhibits JAK2/3 (IC50s: 77 nM/6.49 μM).Formula:C18H21F2N7OPurity:99.82%Color and Shape:SolidMolecular weight:389.4Ref: TM-TQ0010
1mg34.00€2mg46.00€5mg66.00€10mg99.00€25mg205.00€50mg371.00€100mg595.00€200mg833.00€1mL*10mM (DMSO)73.00€CHMFL-FLT3-122
CAS:CHMFL-FLT3-122 is a potent and orally available FLT3 kinase inhibitor used to treat FLT3-ITD positive acute myeloid leukemia.
Formula:C26H29N7O2Purity:99.63%Color and Shape:SolidMolecular weight:471.55MS 154
CAS:MS 154 is a potent PROTAC® targeting mutant EGFR in lung cancer, sparing WT-EGFR; effective in mice, with DC50 of 11-25 nM.Formula:C46H54ClFN8O8Color and Shape:SolidMolecular weight:901.42PF-06459988
CAS:PF-06459988 is a novel, effective, orally active, irreversible, and selective epidermal growth factor receptor (EGFR) mutant inhibitor.Formula:C19H22ClN7O3Purity:98%Color and Shape:SolidMolecular weight:431.88GSK2646264
CAS:GSK2646264 (Compound 44) inhibits SYK (pIC50=7.1) and kinases like LCK, LRRK2; penetrates skin.Formula:C24H26N2O2Color and Shape:SolidMolecular weight:374.48EGFR/ErbB-2 inhibitor-1
CAS:EGFR/ErbB-2 inhibitor-1 is a selective ErbB2/HER2 inhibitor that effectively blocks ErbB2 and HER2 signaling.Formula:C23H15ClFN3OS2Purity:98.93%Color and Shape:SolidMolecular weight:467.97CH6953755
CAS:CH6953755: oral YES1 kinase inhibitor, IC50 1.8 nM, potent, selective, anticancer, halts cell proliferation.Formula:C26H22F2N6O4SPurity:98.87%Color and Shape:SolidMolecular weight:552.55Ref: TM-T10784
1mg55.00€5mg116.00€10mg177.00€25mg348.00€50mg557.00€100mg893.00€1mL*10mM (DMSO)141.00€EGFR-IN-87
CAS:EGFR-IN-87 is an EGFR tyrosine kinase inhibitor with potent inhibitory activity, exhibiting IC50 values of 3.1 nM, 1.3 nM, and 7.1 nM against EGFR_d746-750,Formula:C28H33N7O2Purity:98.64%Color and Shape:SolidMolecular weight:499.61BMS-935177
CAS:BMS-935177 is a reversible BTK inhibitor with IC50 value of 3 nM.Formula:C31H26N4O3Purity:99.89%Color and Shape:SolidMolecular weight:502.56IN-1130
CAS:IN-1130: ALK5 inhibitor, IC50 - 5.3 nM (Smad3), 36 nM (casein), 4.3 μM (p38α MAPK).Formula:C25H20N6OPurity:99.79%Color and Shape:SolidMolecular weight:420.47Zongertinib
CAS:Zongertinib is a human HER2-selective tyrosine kinase inhibitor, a novel TK that is highly selective for covalent binding to the HER2 tyrosine kinase domain (Formula:C29H29N9O2Purity:98.24%Color and Shape:SolidMolecular weight:535.6Ref: TM-T69534
1mg66.00€5mg145.00€10mg222.00€25mg371.00€50mg522.00€100mg708.00€1mL*10mM (DMSO)170.00€BGB-8035
CAS:BGB-8035 is a BTK inhibitor with antitumor activity that inhibits BTK, TEC, and EGFR.BGB-8035 is used in the study of tumors and autoimmune diseases.Formula:C24H31N5O4Purity:96.74%Color and Shape:SolidMolecular weight:453.53JAK-IN-3
CAS:JAK-IN-3 is a potent JAK inhibitor that inhibits JAK3, JAK1, TYK2, and JAK2, and can be used for the study of immune system disorders.Formula:C18H20N4O3Purity:98.04% - 98.19%Color and Shape:SolidMolecular weight:340.38Ref: TM-T11704
1mg126.00€2mg178.00€5mg304.00€10mg492.00€25mg982.00€50mg1,558.00€100mg2,538.00€200mg3,402.00€1mL*10mM (DMSO)334.00€Sevabertinib
CAS:Sevabertinib (BAY 2927088) is an EGFR tyrosine kinase inhibitor, with anticancer activity, used in research on non-small cell lung cancer.Formula:C24H25ClN4O5Purity:99.81%Color and Shape:SolidMolecular weight:484.93WAY-600
CAS:WAY-600 is a potent, ATP-competitive and selective inhibitor of mTOR with IC50 of 9 nM; blocks mTORC1/P-S6K(T389) and mTORC2/P-AKT(S473) but not P-AKT(T308).Formula:C28H30N8OPurity:99.88%Color and Shape:SolidMolecular weight:494.59Ref: TM-T6730
1mg35.00€2mg60.00€5mg92.00€10mg133.00€25mg233.00€50mg344.00€100mg480.00€500mgTo inquire1mL*10mM (DMSO)105.00€ALK-IN-27
CAS:Neladalkib (NVL-655) is an ALK inhibitor with antitumor activity for the study of non-small cell cancers.Formula:C23H22ClFN6OPurity:99.71%Color and Shape:SolidMolecular weight:452.91TAK-020
CAS:TAK-020 is a potent covalent inhibitor of Btk with potential antitumor activity for the study of rheumatoid arthritis and immune-related diseases.Formula:C18H17N5O3Purity:98.66%Color and Shape:SolidMolecular weight:351.36Ref: TM-T9529
1mg138.00€5mg334.00€10mg597.00€25mg1,234.00€50mg1,908.00€100mg2,952.00€1mL*10mM (DMSO)358.00€Ifebemtinib
CAS:Ifebemtinib (BI-853520) is an adhesion plaque kinase inhibitor with anti-tumour activity for the study of breast cancer.Formula:C28H28F4N6O4Purity:98.84% - 99.85%Color and Shape:SolidMolecular weight:588.55Ref: TM-T64167
1mg146.00€5mg245.00€10mg369.00€25mg572.00€50mg882.00€100mg1,243.00€1mL*10mM (DMSO)316.00€KER047
CAS:ALK2-IN-4, a highly effective ALK2 inhibitor.Formula:C26H30FN7OPurity:98.49% - >99.99%Color and Shape:SolidMolecular weight:475.56Ref: TM-T39764
1mg90.00€5mg215.00€10mg349.00€25mg713.00€50mg1,018.00€100mg1,558.00€1mL*10mM (DMSO)236.00€EGFR-IN-1 hydrochloride
CAS:EGFR-IN-1 HCl targets L858R/T790M EGFR mutants over wild-type; IC50: 4 nM in H1975, 28 nM in mutant HCC827 cells.Formula:C28H31ClN6O4Purity:99.16%Color and Shape:SolidMolecular weight:551.04Ref: TM-T11157L
1mg62.00€5mg142.00€10mg205.00€25mg319.00€50mg429.00€100mg587.00€200mg795.00€1mL*10mM (DMSO)190.00€HIF-2α agonist 2
CAS:HIF-2α agonist 2 is an HIF-2α agonist with an EC50 value of 1.68 μM for HIF-2α.Formula:C13H8Br2N2O2SPurity:98.87%Color and Shape:SoildMolecular weight:416.09FIIN-1
CAS:FIIN-1 (FGFR irreversible inhibitor-1) is an irreversible and selective FGFR inhibitor with Kd of 2.8, 6.9, 5.4, 120, 32 and 120 nM for FGFR1, FGFR2, FGFR3,Formula:C32H39Cl2N7O4Purity:98.75%Color and Shape:SolidMolecular weight:656.6Ref: TM-T37426
1mg74.00€2mg98.00€5mg192.00€10mg313.00€25mg520.00€50mg742.00€100mg982.00€500mg2,008.00€Src Inhibitor 3
CAS:Src Inhibitor 3 blocks c-Src kinase (IC50 <3 nM CSK HTRF, <4 nM Caliper), boosting T cell growth from receptor signals.Formula:C34H32ClFN8O4Purity:98.35%Color and Shape:SolidMolecular weight:671.12Ref: TM-T13000
1mg96.00€5mg177.00€10mg304.00€25mg480.00€50mg665.00€100mgTo inquire1mL*10mM (DMSO)264.00€HM43239
CAS:HM43239: oral FLT3 inhibitor; IC50: FLT3 WT 1.1nM, ITD 1.8nM, D835Y 1.0nM; blocks p-STAT5/p-ERK; affects SYK, JAK1/2, TAK1; halts leukemia cell growth.Formula:C29H33ClN6Purity:99.7%Color and Shape:SolidMolecular weight:501.07Ref: TM-T9428
1mg50.00€5mg99.00€10mg158.00€25mg309.00€50mg464.00€100mg647.00€200mg855.00€1mL*10mM (DMSO)109.00€CAY10781
CAS:CAY10781 inhibits NRP-1/VEGF-A binding by 43% at 12.5μM and blocks VEGFR2 phosphorylation in CAD cells.Formula:C11H9N3O3Purity:99.49%Color and Shape:SolidMolecular weight:231.21Ref: TM-T37424
2mg39.00€5mg54.00€10mg77.00€25mg124.00€50mg172.00€100mg316.00€200mg442.00€1mL*10mM (DMSO)79.00€LNK01004
CAS:LNK01004 is a JAK inhibitor that exhibits potent inhibitory effects on JAK1 (IC50: 10 nM), JAK2 (IC50: ＜0.51 nM), and TYK2 (IC50: 1.0 nM). It can concurrently inhibit multiple cytokine-induced p-STAT signaling pathways and is applicable for research on diseases such as atopic dermatitis.Formula:C26H31N7O2Color and Shape:SolidMolecular weight:473.57EGFR-IN-147
CAS:EGFR-IN-147 (compound ID-5841161) is a potent EGFR inhibitor, demonstrating a 14% inhibition rate at a concentration of 1μM. It holds promise for cancer research applications.Formula:C13H13N5OColor and Shape:SolidMolecular weight:255.275VEGFR-2-IN-65
CAS:VEGFR-2-IN-65 (Compound 07) functions as a VEGFR-2 inhibitor. It forms hydrogen bonds with Cys180 and can inhibit tube formation in HUVECs.Formula:C21H18N2O3Color and Shape:SolidMolecular weight:346.379Milpecitinib
CAS:Milpecitinib (Compound 21a) is a potent and selective Janus tyrosine kinase (JAK) inhibitor with anti-inflammatory properties. It shows promise for research in cancer and inflammatory diseases.Formula:C20H20N4O2SColor and Shape:SolidMolecular weight:380.463DA-0157
CAS:DA-0157 is an orally active inhibitor targeting EGFR and ALK, designed to overcome resistance mutations in non-small cell lung cancer (NSCLC). It effectively inhibits the proliferation of Ba/F3-EGFR Del19/T790M/C797S (IC50= 6.9 nM), Ba/F3-EGFR WT (IC50= 0.83 μM), Ba/F3-EML4-ALK-L1196M (IC50= 5.5 nM), and Ba/F3-EML4-ALK (IC50= 7.4 nM). Additionally, DA-0157 inhibits CYP2D6 with an IC50 of 5.26 μM and demonstrates antitumor activity in mouse models.Formula:C31H43BrN7O2PColor and Shape:SolidMolecular weight:656.597FGFR1 inhibitor-16
CAS:FGFR1inhibitor-16 (Compound 89) functions as an FGFR1 inhibitor, demonstrating an inhibition rate of 53.00% at a concentration of 50 μM and 24.95% at 10 μM. It is utilized in tumor research.Formula:C16H9N5O3SColor and Shape:SolidMolecular weight:351.339FAK-IN-3
FAK-IN-3 inhibits FAK, reduces PA-1 cell migration/invasion, and tumor growth, with no major side effects.Formula:C28H28N6O4Color and Shape:SolidMolecular weight:512.56FGFR4-IN-7
FGFR4-IN-7 is a covalent, reversible FGFR4 inhibitor (IC50: 0.42 μM) that blocks the FGFR4 signaling pathway, thereby inducing apoptosis.Formula:C26H25Cl2N5O3Color and Shape:SolidMolecular weight:526.41VEGFR-2-IN-13
VEGFR-2-IN-13 (Compound 19a) is a potent VEGFR-2 inhibitor (IC50: 3.4 nM). vEGFR-2-IN-13 arrests the HepG2 cell cycle in G2/M phase and induces apoptosis.Formula:C24H18N6O2SColor and Shape:SolidMolecular weight:454.5EGFR-IN-44
EGFR-IN-44: potent EGFR kinase inhibitor, orally active, IC50 4.11 nM, 33.57% bioavailability, induces apoptosis, for lung cancer study.Formula:C27H29ClN6O2SColor and Shape:SolidMolecular weight:537.08DBMB
CAS:DBMB is a spleen tyrosine kinase (Syk) inhibitor that significantly suppresses Syk enzyme activity. It possesses anti-inflammatory properties by inhibiting NF-κB signaling, thereby reducing the production of inflammatory mediators such as nitric oxide (NO) and prostaglandin E2 (PGE2). DBMB can be utilized in research on inflammatory diseases.Formula:C24H22N4OColor and Shape:SolidMolecular weight:382.458BTK-IN-8
BTK-IN-8: potent, selective covalent BTK inhibitor; IC50=0.22 nM, Kd=0.91 nM; effective in blood CD69 cells (IC50=0.029 μM).Formula:C26H36N6O3Color and Shape:SolidMolecular weight:480.6JBJ-02-112-05
CAS:JBJ-02-112-05 is a potent, mutant-selective, allosteric and orally active inhibitor of EGFR with an IC 50 of 15 nM for EGFR L858R/T790M [1].Formula:C27H20N4O2SPurity:98%Color and Shape:SolidMolecular weight:464.54EGFR-IN-38
CAS:EGFR-IN-38: low-toxic acrylamide-derived EGFR inhibitor, targets NSCLC, patented for research on EGFR mutation-related diseases.Formula:C25H24ClN7O2Color and Shape:SolidMolecular weight:489.96Flonoltinib sulfate
CAS:Flonoltinib maleate is an orally active dual inhibitor of JAK2/FLT3, with IC50 values of 0.7 nM for JAK2, 4 nM for FLT3, 26 nM for JAK1, and 39 nM for JAK3. It exhibits anticancer properties.Formula:C25H36FN7O5SColor and Shape:SolidMolecular weight:565.661TX2-121-1
CAS:TX2-121-1 targets HER3 for proteasome-mediated degradation to inhibit HER3-dependent signalling and growth.Formula:C42H52N8O3Purity:98%Color and Shape:SolidMolecular weight:716.91E6201
CAS:E6201, a dual kinase inhibitor, blocks MEK1/FLT3 and has anti-tumor/psoriasis effects with low IC50s: ERK2 (5.2 nM), JNK (91 nM), p38 MAPK (19 nM).Formula:C21H27NO6Color and Shape:SolidMolecular weight:389.44Paeoniflorin-6′-O-benzene sulfonate
CAS:Paeoniflorin-6′-O-benzene sulfonate (CP-25) acts as an inhibitor of G protein-coupled receptor kinase 2 (GRK2), preventing its translocation to the cell membrane and inhibiting the JAK1/STAT3 signaling pathway. It suppresses HaCaT cell proliferation induced by IL-17A/CXCL2. In mouse models, CP-25 reduces the levels of inflammatory cytokines and chemokines such as IL-17A, IL-17F, IFN-γ, TNF-α, IL-22, IL-23, CXCL2, CXCL3, and CXCL9, thereby alleviating psoriasis induced by Imiquimod.Formula:C29H32O13SColor and Shape:SolidMolecular weight:620.622Protein kinase inhibitor 13
CAS:Protein kinase inhibitor 13 (Compound I-90) functions as a kinase inhibitor, specifically targeting kinases such as PIM-1, CDK-2, GSK-3, and SRC.Formula:C19H20FN5OSColor and Shape:SolidMolecular weight:385.458CGP062464
CAS:CGP062464 is an inhibitor of the tyrosine kinase c-Src, with an IC50 of less than 50 nM. It is utilized in research related to osteoporosis and tumor-induced hypercalcemia.Formula:C18H14N4Color and Shape:SolidMolecular weight:286.331HER2-IN-8
CAS:HER2-IN-8 is an inhibitor of HER-2 that can be used in the study of cancer and inflammation-related diseases.Formula:C26H25F2N9O3Color and Shape:SolidMolecular weight:549.53FGFR2/3-IN-2
CAS:FGFR2/3-IN-2 (compound 10) is an orally active inhibitor targeting FGFR2 and FGFR3. It exhibits IC50 values of 3.7 nM for FGFR2 and 31.2 nM for FGFR3, with a pre-incubation time of 1 hour. FGFR2/3-IN-2 demonstrates selectivity over FGFR1/4 and other kinases, and does not cause diarrhea or increased serum phosphate in vivo. In the SNU-16 gastric cancer model, FGFR2/3-IN-2 can induce tumor stasis or regression.Formula:C29H23FN6O3Color and Shape:SolidMolecular weight:522.53EGFR-IN-159
CAS:EGFR-IN-159 (compound 12) is a dihydropyrimidine and a potent EGFR inhibitor with an IC50 of 29.00 nM. It exhibits dose-dependent inhibition of EGFR and HER2. The compound shows cytotoxicity against MCF-7 breast cancer cells and Vero cells with IC50 values of 16.07 μg/mL and 35.98 μg/mL, respectively. EGFR-IN-159 does not cross the blood-brain barrier (BBB) and demonstrates significant anticancer activity.Formula:C21H23N3O5Color and Shape:SolidMolecular weight:397.424Gamendazole
CAS:Gamendazole is a novel drug candidate for male contraception. It has been shown to reduce fertility in male rats without affecting testosterone levels.Formula:C18H11Cl2F3N2O2Purity:98%Color and Shape:SolidMolecular weight:415.19
